ErgoSenseBrain

ErgoSenseBrain provides software technology and deep analytics of movement which can provide critical insights in the early development of many neurodegenerative disorders.

Neuro-degenerative diseases often develop slowly with time allowing people to adapt to their changing condition which can manifest in many different ways, e.g., changes in the neuro-muscular kinetic chain. Even when individuals realize that "something is wrong", medical tests often fail to provide a definitive diagnosis. Many diagnostic tests are too expensive or require trained technicians and are still not sensitive enough to detect the onset of diseases such as MS and Parkinson's.

ErgoSensePro Inc has developed unique algorithms for the deep analysis of movement and work generation for athletes and patients. We have validated these algorithms Scientifically and are continuing validation with University trials and a major Basketball Academy in Greece (as beta user). We can provide predictive and personalized solutions for movement and optimal training/therapy.

We believe the algorithms behind ErgoSensePro are powerful enough to detect the early onset of neurodegenerative diseases by providing deep analytics of movement, identifying abnormal patterns in neuromuscular function, and correlating to neurodegeneration.

If we can detect the early onset of neurodegenerative diseases one year earlier in 20% of cases that translates to ten million people having earlier diagnosis, treatments, and better quality of life.

Our solution will benefit the elderly and also those with a familiar history or genetic predisposition in neurodegenrative diseases. Our solution will mostly help Doctors in all aspects: from detection, monitoring of progression, and treatment.

Our solution will be deployed as software operating from a tablet and easily implemented using, at first, commercial wearables that can measure velocity and later on purpose built wearables.

Software orders - 100 Doctors download our software

Patient entries through software - 10,000 high-risk individuals are examined using the ErgoSenseBrain system

Feedback from software - 100 cases of early onset neurodegenerative diseases confirmed after one year (true positives)

What makes Ergo unique is that for the first time we can predict how a subject will respond to a training program, compare subjects in a scientific and objective manner, and develop personalized and optimal training programs for athletes and patients depending on their needs.

A key part of our approach is the unique movement evaluation tests with the underlying deep-tech algorithms. These algorithms are so powerful that they can potentially pick-up on movement abnormalities that are otherwise invisible to simple motion analysis. These abnormalities could be a result of injuries, unbalanced neuromuscular development or even neurodegenerative diseases.

ErgoSenseBrain can make a huge impact in third world countries and underserved communities.

Based on the growing experience of ErgoSensePro with athletes and patients and the use of commercial wearables to obtain movement data we can modify parts of the ErgoSensePro algorithms so an individual with minimal training can perform patient testing using simple wearables. The data can be sent to a small number of trained physicians who will analyze the output metrics of the ErgoSensePro software.

In this way patients, trained personnel, physicians, and ErgoSenseBrain support personnel can all work to solve big global problems.

ErgoSenseBrain will be provided as a software product to physicians.

Health practitioners will use approved commercial wearable sensors (may partner with a specific provider to reduce costs) to perform evaluation tests for different basic movements (e.g., standing up, pushing, pulling) and enter the data to our software interface.

Information on abnormalities in the evaluation metrics could be identified from day one but the ErgoSenseBrain approach will become very powerful once outcome information becomes available and is correlated with those that do in fact develop  neurodegenerative diseases.

Our main business is with professional sports teams and we have early traction with the top basketball academy in Greece. We expect to have first clients by the end of 2017 and be profitable by mid-2018. This will provide direct support for our many efforts in the healthcare applications including ErgoSenseBrain.

The success of ErgoSensePro will also increase our business credibility and help us secure funds from investors and/or non-profit agencies.

We have initiated procedures to set-up a team in Boston to examine the rehabilitation applications of ErgoSensePro. This same team could become involved in the ErgoSenseBrain activities.

ErgoSenseBrain will provide information not otherwise available.
This additional information will have clear value.

However it is still unclear how valuable this information will be.
It is very difficult to determine the value a priorias Brain Health is a rapidly developing field and the types and sources of information being provided to health practitioners are evolving rapidly.

However, we differentiate ourselves with the unique capabilities of ErgoSensePro and their deep-tech movement evaluation algorithms which makes us confident that the information we provide will indeed be valuable for the early detection of neurodegenerative diseases.

http://www.mitefgreece.org/ergosensepro-software/

http://www.mitefgreece.org/mitef-greece-startup-competition-2017-6/

http://www.platform.gr/life/prosopa/70785-aleks-aleksopoulos-neoi-pou-epixeiroyn-theloume-na-allaksoume-ton-tropo-proponisis-gia-tous-athlites-tou-21ou-aiona

We started ErgoSensePro by targeting professional coaches and teams as the most obvious application of the ErgoSensePro deep-tech algorithms are in  training programs and athlete evaluation in Sports.

However, the more challenging applications with immense social value are in healthcare. It is our deep desire to implement these technologies to healthcare applications including rehabilitation and diagnostics of neurodegenerative diseases.

This is our goal and mission as a company.

Solve could benefit us by connecting with open-minded physicians in the US and possibly wearable device companies as the existing wearables will need to be modified to best suit our application.

Currently we do not have partners but have some connections to physicians via Health Innovators at CIC and connections to medical device manufacturers in Greece.

No companies posses the deep-tech algorithms of ErgoSensePro so we have no competitors.